Anzeige
Meldung des Tages: Diese Zahlen lügen nicht: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Novavax News

Aktie
WKN:  A2PKMZ ISIN:  US6700024010 US-Symbol:  NVAX Branche:  Biotechnologie Land:  USA
7,52 €
+0,19 €
+2,59%
17.04.26
Depot/Watchlist
Marktkapitalisierung *
942,83 Mio. €
Streubesitz
29,59%
KGV
3,13
Nachhaltigkeits-Score
25 %
Index-Zuordnung
-

Novavax News

13.12.24 - PR Newswire
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone PR Newswire
10.12.24 - PR Newswire
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-​Alone Influenza PR Newswire
04.12.24 wallstreetONLINE Redaktion
Aktie steigt: Novavax: Deal mit Novo Nordisk!
Novavax gab am Mittwoch bekannt, seine Produktionsanlage in der Tschechischen Republik für 200 Millionen US-Dollar an den Wegovy-​Hersteller Novo Nordisk zu verkaufen. Im ...
04.12.24 - PR Newswire
Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million PR Newswire
30.11.24 - Börse-Global
Novavax Aktie: Neutralität im Fokus der Analyse
Die Novavax-​Aktie verzeichnete am 30. November 2024 eine positive Entwicklung an der Börse. Der Biotechnologie-​Konzern aus Maryland konnte im Tagesverlauf einen ...
18.11.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX PR Newswire
15.11.24 - PR Newswire
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) PR Newswire
13.11.24 - PR Newswire
Novavax to Participate in Jefferies London Healthcare Conference
Novavax to Participate in Jefferies London Healthcare Conference PR Newswire
12.11.24 - PR Newswire
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights PR Newswire
11.11.24 - PR Newswire
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-​alone Influenza Phase 3 Trial PR Newswire
10.11.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX PR Newswire
04.11.24 - PR Newswire
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024 PR Newswire
04.11.24 - PR Newswire
Åsa Manelius Named Managing Director of Novavax AB Site
Åsa Manelius Named Managing Director of Novavax AB Site PR Newswire
02.11.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX PR Newswire
27.10.24 - PR Newswire
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm
NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm PR Newswire
17.10.24 - Börse-Global
Novavax Aktie: FDA-Stopp erschüttert Impfstoff-Hoffnungen
Der Aktienkurs des Impfstoffherstellers Novavax erlebte am Mittwoch einen dramatischen Einbruch von über 20% an der NASDAQ. Auslöser war die Entscheidung der US-...
16.10.24 - PR Newswire
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Update on Novavax's COVID-19-Influenza Combination and Stand-​alone Influenza Phase 3 Trial PR Newswire
09.10.24 - PR Newswire
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU PR Newswire
25.09.24 - PR Newswire
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
Novavax Names Dr. Ruxandra Draghia-​Akli as New Executive Vice President and Head of Research & Development PR Newswire
13.09.24 - PR Newswire
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. PR Newswire

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »